FY2017 Earnings Forecast for Sierra Oncology Inc Issued By SunTrust Banks (SRRA)

Sierra Oncology Inc (NASDAQ:SRRA) – Investment analysts at SunTrust Banks upped their FY2017 EPS estimates for Sierra Oncology in a research note issued on Thursday. SunTrust Banks analyst Y. Suneja now forecasts that the biotechnology company will post earnings per share of ($0.84) for the year, up from their prior forecast of ($0.92). SunTrust Banks also issued estimates for Sierra Oncology’s Q4 2017 earnings at ($0.20) EPS, Q1 2018 earnings at ($0.21) EPS, Q2 2018 earnings at ($0.22) EPS, Q3 2018 earnings at ($0.23) EPS, Q4 2018 earnings at ($0.19) EPS, FY2018 earnings at ($0.86) EPS, FY2020 earnings at ($1.00) EPS and FY2021 earnings at ($1.00) EPS.

Sierra Oncology (NASDAQ:SRRA) last released its quarterly earnings data on Wednesday, November 8th. The biotechnology company reported ($0.19) earnings per share for the quarter, topping the consensus estimate of ($0.22) by $0.03.

TRADEMARK VIOLATION NOTICE: “FY2017 Earnings Forecast for Sierra Oncology Inc Issued By SunTrust Banks (SRRA)” was originally reported by Markets Daily and is owned by of Markets Daily. If you are accessing this story on another site, it was illegally stolen and reposted in violation of international copyright legislation. The legal version of this story can be viewed at https://www.themarketsdaily.com/2017/11/15/fy2017-earnings-forecast-for-sierra-oncology-inc-issued-by-suntrust-banks-srra.html.

Several other equities research analysts have also weighed in on the company. Zacks Investment Research lowered Sierra Oncology from a “hold” rating to a “sell” rating in a research note on Thursday, October 26th. Jefferies Group LLC raised Sierra Oncology from a “hold” rating to a “buy” rating in a research note on Monday, October 23rd. Finally, ValuEngine raised Sierra Oncology from a “strong sell” rating to a “sell” rating in a research report on Friday, September 1st. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the stock. Sierra Oncology currently has a consensus rating of “Hold” and an average price target of $4.00.

Shares of Sierra Oncology (SRRA) opened at $1.94 on Monday. Sierra Oncology has a one year low of $1.10 and a one year high of $2.25.

An institutional investor recently bought a new position in Sierra Oncology stock. FMR LLC bought a new position in Sierra Oncology Inc (NASDAQ:SRRA) in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 197,100 shares of the biotechnology company’s stock, valued at approximately $302,000. FMR LLC owned 0.38% of Sierra Oncology as of its most recent SEC filing. Institutional investors own 55.65% of the company’s stock.

Sierra Oncology Company Profile

Sierra Oncology, Inc, formerly ProNAi Therapeutics, Inc, is a clinical-stage drug development company. The Company’s lead drug candidate, SRA737, is orally bioavailable small molecule inhibitor of Checkpoint kinase 1 (Chk1), a key cell cycle checkpoint and central regulator of the deoxyribonucleic acid (DNA) Damage Response (DDR) network.

Earnings History and Estimates for Sierra Oncology (NASDAQ:SRRA)

Receive News & Ratings for Sierra Oncology Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sierra Oncology Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply